Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Authors:
- Soo-Youn LeeSLSoo-Youn Lee
- Seung-Tae LeeSLSeung-Tae Lee
- Jong-Won KimJKJong-Won Kim
- 31 May 2007
- journal article
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 40 (3) , 448-452
Abstract
We examined the contribution of CYP2C9 and CYP2C19 genotypes and drug interactions to the phenytoin metabolism among 97 Korean epileptic patients to determine if pharmacogenetic testing could be utilized in routine clinical practice. The CYP2C9 polymorphism is a wellknown major genetic factor responsible for phenytoin metabolism. The CYP219 polymorphism, with a high incidence of variant alleles, has a minor influence on phenytoin treated Koran patients. Using a multiple regression model for evaluation of the CYP2C9 and CYP2C19 genotypes, together with other non-genetic variables, we explained 39.6% of the variance in serum phenytoin levels. Incorporation of genotyping for CYP2C9 and CYP2C19 into a clinical practice may be of some help in the determination of phenytoin dosage. However, because concurrent drug treatment is common in patients taking phenytoin and many environmental factors are likely to play a role in drug metabolism, these factors may overwhelm the relevance of CYP polymorphisms in the clinical setting. Further investigations with an approach to dose assessment that includes comprehensive interpretation of both pharmacogenetic and pharmacokinetic data along with understanding of the mechanism of drug interactions in dosage adjustment is warranted.Keywords
This publication has 17 references indexed in Scilit:
- Dosage Recommendation of Phenytoin for Patients with Epilepsy with Different CYP2C9/CYP2C19 PolymorphismsTherapeutic Drug Monitoring, 2004
- Phenytoin Intoxication Induced by FluvoxamineTherapeutic Drug Monitoring, 2001
- The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population PharmacokineticsEpilepsia, 1998
- A Mechanistic Approach to Antiepileptic Drug InteractionsAnnals of Pharmacotherapy, 1998
- Genetic analysis of CYP2C9 polymorphism in a Japanese populationPharmacogenetics, 1997
- Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy*Clinical Pharmacology & Therapeutics, 1997
- Elevated Serum Phenytoin Concentrations Associated With Coadministration of SertralineJournal of Clinical Psychopharmacology, 1997
- Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populationsPharmacogenetics, 1997
- Reduction in phenytoin clearance caused by cimetidineEuropean Journal of Clinical Pharmacology, 1983
- Effect of Antacids on Phenytoin BioavailabilityTherapeutic Drug Monitoring, 1981